

## **Volume 1.**

### **Part I. Introduction**

1. *The Nature of Osteoporosis*
2. *The Bone Organ System: Form and Function*

### **Part II. Developmental, Cellular and Molecular Biology of Bone**

3. *Development of the Skeleton*
4. *The Skeletal Stem Cell*
5. *Osteoclast Biology*
6. *Osteoblast Biology: Developmental Origin and Interactive Nature of Osteoblasts*
7. *Osteocytes*
8. *The Regulatory Role of Matrix Proteins in Mineralization of Bone*

### **Part III. Skeletal Hormones and Regulatory Factors**

9. *Parathyroid Hormone and Parathyroid Hormone-Related Protein*
10. *Phosphatonins*
11. *Skeletal Growth Factors*
12. *WNT Signaling in Skeletal Homeostasis and Diseases*

### **Part IV. Biomechanics and Mechanobiology**

13. *The Mechanical Behavior of Bone*
14. *Cellular and Molecular Mechanotransduction in Bone*
15. *Adaptation of Skeletal Structure to Mechanical Loading*
16. *Biomechanics of Hip and Vertebral Fractures*

### **Part V. Epidemiology of Osteoporosis**

17. *Epidemiologic Methods in Studies of Osteoporosis*
18. *Genetics of Osteoporosis*
19. *Race, Ethnicity, and Osteoporosis*
20. *Geographic Variability in the Incidence of Hip and Vertebral Fractures*
21. *Nutrition and Osteoporosis*
22. *Physical Activity, Exercise and Skeletal Health*
23. *Reproductive and Hormonal Factors and the Risk for Osteoporosis*
24. *Clinical and Epidemiological Studies: Skeletal Changes across Menopause*
25. *Osteoporosis in Men: What is Similar and What is Different?*
26. *Falls as Risk Factors for Fracture*
27. *Impact of Physical Characteristics and Lifestyle Factors on Bone Density and Fractures*
28. *Imminent Fracture Risk and Disability Post Fracture*
29. *Economics of Osteoporosis*

### **Part VI. General Pathophysiology of Osteoporosis**

30. *Skeletal Heterogeneity and the Purposes of Bone Remodeling*
31. *On the Evolution and Contemporary Roles of Bone Remodeling*
32. *Estrogen Deficiency and the Pathogenesis of Osteoporosis*
33. *Cytokines and the Pathogenesis of Osteoporosis*
34. *Bone and Fat*
35. *Bone, Muscle, and Sarcopenia*
36. *Bone Mineral Acquisition in Utero and During Infancy and Childhood*
37. *Osteoporosis in Childhood and Adolescence*
38. *Osteoporosis in Premenopausal Women, Pregnancy, and Lactation*

39. *Bone and the Microbiome*

**Volume 2.**

**Part VII. Impact of Comorbidity and Medications on Skeletal Health**

- 40. *Immobilization Osteoporosis*
- 41. *Osteoporosis in Neurological Disorders: Parkinson's Disease, Stroke, and Multiple Sclerosis--July 28, 2019*
- 42. *Effects on the Skeleton from Medications Used to Treat Non-skeletal Disorders*
- 43. *Osteoporosis associated with gastrointestinal disorders; celiac and inflammatory bowel diseases*
- 44. *Osteoporosis Associated with Eating Disorders*
- 45. *Glucocorticoid-Induced Osteoporosis and Cushing's Syndrome*
- 46. *Thyroid Hormone, Thyroid Medication, and the Skeleton*
- 47. *The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism*
- 48. *Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis*
- 49. *Human Immunodeficiency Virus and Osteoporosis*
- 50. *Diabetes, Diabetic Medications, and Risk of Fracture*
- 51. *Skeletal Health after Bariatric Surgery*
- 52. *Osteoporosis in Organ Transplant Patients*
- 53. *Osteoporosis Associated with Rheumatologic Disorders*
- 54. *Osteoporosis Associated with Chronic Kidney Disease*
- 55. *Relationship Between Periodontal Disease, Tooth Loss and Osteoporosis*
- 56. *Impact of Breast Cancer and its treatment on Bone Loss and Fracture Risk – Pathophysiology and Management*
- 57. *Management of Bone Health in Men with Prostate Cancer*
- 58. *Impact of MGUS and Myeloma on Skeletal Health*
- 59. *Renal Stone Disease, Hypercalciuria and Osteoporosis: Use of Thiazides and Alkali for Osteoporosis*
- 60. *Sleep Disorders and Osteoporosis*

**Part VIII. Diagnosis and Evaluation 61. Evaluation of the Osteoporosis Patient**

- 62. *Who Should be Screened for Osteoporosis?*
- 63. *Vertebral Fracture Identification*
- 64. *Noninvasive Imaging Techniques and Fracture Risk Assessment*
- 65. *Biochemical Markers of Bone Turnover in Osteoporosis*
- 66. *A Comparison of Fracture Risk Assessment Tools*

**Part IX. Patient Management**

- 67. *Orthopedic Aspects of Osteoporosis*
- 68. *Fall Prevention Interventions*
- 69. *Exercise and Other Physical Therapy Interventions in the Management of Osteoporosis*
- 70. *Calcium and Vitamin D in the Management of Osteoporosis*
- 71. *Nutrients Beyond Calcium and Vitamin D to Treat Osteoporosis*
- 72. *Condition Still Critical: Compliance and Persistence with Osteoporosis Medications*

**Part X. Pharmacotherapeutics**

- 73. *Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis*

- 74. Bisphosphonates Pharmacology and Use in the Treatment of Osteoporosis*
- 75. Denosumab for the Treatment of Osteoporosis*
- 76. Teriparatide and Abaloparatide Treatment for Osteoporosis*
- 77. Calcitonin in Osteoporosis*
- 78. Androgens*
- 79. Long-term Bisphosphonate Treatment: Continuation and Interruption*
- 80. Romosozumab in the Treatment of Postmenopausal Osteoporosis*
- 81. Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs*

**Part XI. New Directions**

- 82. Longterm Treatment Strategies and Goal Directed Therapy*